REVVITY, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 105.7 USD | +0.14% |
|
+2.42% | -3.33% |
| 04-30 | TD Cowen Adjusts Price Target on Revvity to $130 From $123 | MT |
| 04-30 | JPMorgan Adjusts Price Target on Revvity to $105 From $100, Neutral Rating Maintained | MT |
| Sales 2024 * | 2.79B 222B | Sales 2025 * | 3B 238B | Capitalization | 13.02B 1,035B |
|---|---|---|---|---|---|
| Net income 2024 * | 246M 19.55B | Net income 2025 * | 330M 26.22B | EV / Sales 2024 * | 5.51 x |
| Net Debt 2024 * | 2.38B 189B | Net Debt 2025 * | 2.01B 160B | EV / Sales 2025 * | 5.02 x |
| P/E ratio 2024 * |
53
x | P/E ratio 2025 * |
39.4
x | Employees | 11,500 |
| Yield 2024 * |
0.27% | Yield 2025 * |
0.27% | Free-Float | 99.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Revvity, Inc.
More recommendations
More press releases
More news
| 1 day | +0.14% | ||
| 1 week | +2.42% | ||
| Current month | +3.12% | ||
| 1 month | +3.27% | ||
| 3 months | +2.04% | ||
| 6 months | +20.28% | ||
| Current year | -3.33% |
1 week
102.03
106.98
1 month
97.32107.34
Current year
97.32115.00
1 year
79.50131.96
3 years
79.50203.16
5 years
62.91203.16
10 years
38.96203.16
| Managers | Title | Age | Since |
|---|---|---|---|
Prahlad Singh
CEO | Chief Executive Officer | 59 | 30/04/14 |
| Director of Finance/CFO | 35 | 30/09/18 | |
Madhuri Hegde
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexis Michas
CHM | Chairman | 66 | 31/12/00 |
Pascale Witz
BRD | Director/Board Member | 57 | 29/10/17 |
| Director/Board Member | 70 | 26/07/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 17.77% | 13 M€ | -.--% | ||
| 1.41% | 2 M€ | +9.27% | ||
| 1.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/05/24 | 105.7 | +0.11% | 238 468 |
| 13/05/24 | 105.6 | +0.72% | 550,835 |
| 10/05/24 | 104.8 | +0.44% | 608,005 |
| 09/05/24 | 104.3 | +1.47% | 403,258 |
| 08/05/24 | 102.8 | -0.33% | 489,319 |
Delayed Quote Nyse, May 14, 2024 at 06:17 pm
More quotes
Revvity, Inc. (formerly PerkinElmer, Inc.) specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales (including intragroup) break down by family of products as follows:
- medical diagnosis equipment (61%);
- analytical tools and instruments (39%): biological molecular research tools, thermal analysis software, chemical and environmental measurement tools, genetic screening instruments, reagents, etc.
Net sales are distributed geographically as follows: the United States (46.7%), China (14.4%), the United Kingdom (4.1%) and other (34.8%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
105.6
USD
Average target price
123.6
USD
Spread / Average Target
+17.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.33% | 13.02B | |
| +11.08% | 225B | |
| +10.92% | 186B | |
| +13.02% | 135B | |
| +25.96% | 107B | |
| +0.91% | 63.56B | |
| +6.74% | 51.32B | |
| +12.30% | 51.04B | |
| +8.01% | 43.3B | |
| +4.53% | 36.99B |
- Stock Market
- Equities
- RVTY Stock
